Who is sponsoring NCT05057351?

NCT05057351 is sponsored by Greenpharma S.A.S..

What drugs are being tested in NCT05057351?

Interventions in NCT05057351: Isopentenyltheophylline 0.44% + Glycerin 4.56%, Glycerin 4.56%.

What condition does NCT05057351 study?

NCT05057351 studies Mild to Moderate Atopic Dermatitis.

Is NCT05057351 still recruiting?

NCT05057351 is currently completed. Last updated 27 September 2021.

Last reviewed 2021-09-27 · How we verify

NCT05057351

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis

Completed NA Last updated 27 September 2021

What this trial tests

NA trial testing Isopentenyltheophylline 0.44% + Glycerin 4.56% in Mild to Moderate Atopic Dermatitis in 44 participants. Completed in 31 March 2021.

Timeline

1 September 2020

Primary endpoint
30 November 2020

31 March 2021

Quick facts

Lead sponsor	Greenpharma S.A.S.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	44
Start date	1 September 2020
Primary completion	30 November 2020
Estimated completion	31 March 2021
Sites	1 location across Italy

Drugs / interventions tested

Isopentenyltheophylline 0.44% + Glycerin 4.56%
Glycerin 4.56%

Conditions studied

Mild to Moderate Atopic Dermatitis — all drugs for Mild to Moderate Atopic Dermatitis →

Sponsor

Greenpharma S.A.S.

Who can join

18 and older, any sex, with Mild to Moderate Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of safety and clinical efficacy of an active ingredient versus placebo for the treatment of mild to moderate Atopic Dermatitis (AD) adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature.
Sideris N, Paschou E, Bakirtzi K, Kiritsi D, et al · · 2022 · cited 28× · PMID 36078904 · DOI 10.3390/jcm11174974

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05057351 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Greenpharma S.A.S.
Last refreshed: 27 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05057351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing